Needham raised the firm’s price target on Unity (U) to $33 from $26 and keeps a Buy rating on the shares after its Q4 results. The firm is ...

Morgan Stanley raised the firm’s price target on Unity (U) to $32 from $26 and keeps an Overweight rating on the shares. Unity will start ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their mutation type, is being tested in human trials in the UK and Europe.

Organoids were cultured from healthy donor iPSC sources and differentiated using the human iPSC-derived Cerebral Organoid ...

Accurate monitoring of particle size and growth is essential to ensure scalability in the development of transfection vectors ...